Recent EDIT News
- Editas Medicine Announces Proposed Public Offering • GlobeNewswire Inc. • 05/26/2026 10:15:03 AM
- Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress • GlobeNewswire Inc. • 05/26/2026 10:01:00 AM
- Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting • GlobeNewswire Inc. • 05/14/2026 10:01:00 AM
- Editas Medicine Announces First Quarter 2026 Results and Business Updates • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences • GlobeNewswire Inc. • 04/27/2026 08:31:00 PM
- Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference • GlobeNewswire Inc. • 03/27/2026 11:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/09/2026 08:50:10 PM
- Editas Medicine shares edge higher after Q4 earnings and revenue top estimates • IH Market News • 03/09/2026 01:48:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 11:02:57 AM
- Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates • GlobeNewswire Inc. • 03/09/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:56:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:49:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:48:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2026 09:35:09 PM
- Editas Medicine to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/23/2026 02:00:00 PM
- Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine • GlobeNewswire Inc. • 01/28/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2025 09:39:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2025 09:38:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/01/2025 10:06:47 PM
- Editas Medicine Announces Third Quarter 2025 Results and Business Updates • GlobeNewswire Inc. • 11/10/2025 12:00:00 PM
- Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 • GlobeNewswire Inc. • 11/03/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2025 08:31:21 PM
- Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress • GlobeNewswire Inc. • 10/09/2025 03:01:00 PM
- Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences • GlobeNewswire Inc. • 10/06/2025 01:00:00 PM
- Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus • PR Newswire (US) • 09/25/2025 01:15:00 PM
